Corvus Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| · · Year Ended December 31, | |||||||||
| · 2024 · 2023 · 2022 | |||||||||
| Cash flows from operating activities · · · · | |||||||||
| Net loss | | $(62,293) | | $(27,029) | | $(41,307) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | ||||||
| Depreciation and amortization | | 85 | | 151 | | 367 | |||
| Accretion related to marketable securities | | (1,141) | | (894) | | (170) | |||
| Stock-based compensation | | 3,003 | | 2,147 | | 2,692 | |||
| Gain from sale of property and equipment | | (5) | | — | | (22) | |||
| Change in fair value of warrant liability | | 33,377 | | — | | — | |||
| Loss from equity method investment | | 3,197 | | 5,284 | | 10,005 | |||
| Changes in operating assets and liabilities: | | | | | |||||
| Accounts receivable - related party | | (49) | | 562 | | (81) | |||
| Prepaid and other current assets | | (1,587) | | (8) | | 581 | |||
| Operating lease right-of-use asset | | | (28) | | | 1,068 | | | 973 |
| Other assets | | | (543) | | | 40 | | | 107 |
| Accounts payable | | 1,057 | | (451) | | 411 | |||
| Accrued and other liabilities | | (245) | | (3,578) | | 467 | |||
| Operating lease liability | | | (252) | | | (1,227) | | | (1,046) |
| Net cash used in operating activities | | (25,424) | | (23,935) | | (27,023) | |||
| Cash flows from investing activities | | | | ||||||
| Purchases of marketable securities | | (70,119) | | (47,048) | | (66,191) | |||
| Maturities of marketable securities | | 42,630 | | 62,623 | | 43,162 | |||
| Purchases of property and equipment | | — | | (34) | | (269) | |||
| Proceeds from sale of property and equipment | | | 5 | | | – | | | 22 |
| Net cash (used in) provided by investing activities | | (27,484) | | 15,541 | | (23,276) | |||
| Cash flows from financing activities | | | | ||||||
| Proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties) | | 16,405 | | — | | — | |||
| Proceeds from issuance of pre-funded warrants, net (includes $1,769 in aggregate gross proceeds from related parties) | | 5,031 | | — | | — | |||
| Proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties) | | 8,934 | | — | | — | |||
| Proceeds from the exercise of common stock warrants | | | 18,590 | | | — | | — | |
| Proceeds from issuance of common stock in connection with at-the-market offering, net | | | — | | | 7,843 | | | — |
| Proceeds from exercise of common stock options | | 68 | | 12 | | — | |||
| Net cash provided by financing activities | | 49,028 | | 7,855 | | 0 | |||
| Net decrease in cash and cash equivalents | | (3,880) | | (539) | | (50,299) | |||
| Cash and cash equivalents at beginning of the period | | 12,620 | | 13,159 | | 63,458 | |||
| Cash and cash equivalents at end of the period | | $8,740 | | $12,620 | | $13,159 | |||
| Supplemental disclosures of cash flow information | | | | ||||||
| Reclassification of common stock warrant liability into additional paid-in capital upon exercise of common stock warrants | | $13,401 | | $— | | $— | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.